Immunodeficient Animal Model Construction and Testing: A Complete Technical Guide

Immunodeficient animal models—including nude, SCID, NOD-SCID, and NSG-class mice—are the foundational in vivo platforms for tumor xenograft studies, humanized immune system reconstruction, and preclinical drug evaluation. This technical guide explains how these models are constructed, which genetic, immunological, and microbiological parameters must be verified, and how accredited third-party laboratories validate model quality in accordance with GB, ISO, and related recognized standards.

Technical Overview

Immunodeficient animal models are genetically defined laboratory rodents that lack one or more functional components of the immune system. Because they do not reject xenogeneic—particularly human—cells and tissues, they serve as the core in vivo platform for oncology, hematology, immunology, stem cell biology, and preclinical pharmacology. Modern model construction combines targeted gene editing, controlled breeding, and embryo rederivation to produce animals with defined genetic lesions, stable and reproducible phenotypes, and standardized specific pathogen-free (SPF) microbiological status.

Comprehensive testing after construction is essential to confirm four pillars of model quality: (1) the presence and homozygosity of the intended genetic lesion, (2) the depth and stability of the immunodeficient phenotype, (3) the absence of adventitious infectious agents, and (4) the functional capacity of the model to accept human xenografts or support reconstitution of a human immune system. Quality management systems aligned with ISO 9001, combined with laboratory animal standards such as GB 14922, GB 14923, and GB 14925, form the reference framework for model development and release testing.

Principal Model Classes

• Nude mice and rats (Foxn1 mutation): athymic animals lacking mature T cells; B cells and NK cells remain functional; widely used for established human tumor xenografts.
• SCID mice (Prkdc mutation): deficient in both T and B lymphocytes due to defective V(D)J recombination; may exhibit age-dependent immune "leakiness".
• NOD-SCID mice: Prkdc deficiency combined with the NOD background, adding hemolytic complement deficiency and impaired macrophage and dendritic cell function.
• Severe combined strains (NSG/NOG/NCG class, IL2Rγ-null): IL2rg knockout eliminates NK cells and disables cytokine signaling, producing the most permissive hosts for human hematopoietic stem cell (HSC) engraftment and patient-derived xenografts (PDX).
• Humanized derivatives: hu-HSC (CD34+ cell reconstituted), BLT, and PBMC-humanized models built on severe immunodeficient backgrounds for immuno-oncology and infectious disease research.

Construction Strategies

• Targeted gene editing: CRISPR-Cas9 or equivalent nucleases used to introduce frameshift mutations in Foxn1, Prkdc, Il2rg, Rag1, or Rag2 loci, followed by off-target evaluation and founder screening.
• Crossbreeding: combining multiple immune-deficient loci (for example, NOD × SCID × Il2rg-null) to achieve cumulative immunodeficiency.
• Backcrossing: at least ten generations of backcrossing onto a defined inbred background to stabilize genetic uniformity.
• Rederivation: embryo transfer or cesarean derivation into barrier production facilities to establish SPF status before colony expansion.
• Cryopreservation: embryo or sperm banking to secure genetic resources and enable strain recovery.

Testing Samples

Founder and Early-Generation Animals

F0 founders and F1–F3 offspring are sampled to verify germline transmission of the edit, confirm zygosity, exclude mosaicism, and establish that the intended phenotype is expressed before colony expansion begins.

Established Breeding Colonies

Routine samples from breeding nuclei and sentinel animals are collected on a scheduled basis to monitor genetic drift, microbiological status, and phenotype stability across generations.

Humanized and Xenograft-Bearing Animals

Animals undergoing CD34+ HSC reconstitution, PBMC transfer, or tumor inoculation are sampled longitudinally to quantify engraftment kinetics, chimerism levels, and tumor take rates.

Specimen Types

• Tail tip or ear punch tissue for genomic DNA extraction and genotyping.
• Peripheral blood for flow cytometry, complete blood counts, and serology.
• Bone marrow, spleen, thymus, and lymph nodes for immunophenotyping and histology.
• Feces, fur, and oral/anal swabs for bacteriological and parasitological monitoring.
• Tumor tissue from xenograft-bearing animals for histopathology and biomarker analysis.
• Environmental samples from isolators and individually ventilated cages (IVC) for hygiene verification.

Testing Items

Testing programs are structured around genetic, immunological, microbiological, and functional-performance modules. Typical items include:

• Genotype confirmation of the target mutation (homozygous/heterozygous status) by allele-specific PCR and sequencing.
• Copy number variation analysis and screening for potential off-target editing events.
• Background strain identity verification using SNP or microsatellite marker panels.
• T cell, B cell, and NK cell quantification by multiparameter flow cytometry (CD3, CD4, CD8, CD19, B220, NK1.1, CD49b markers).
• Serum immunoglobulin levels (IgM, IgG) by ELISA to confirm humoral immunodeficiency.
• Lymphocyte proliferation responses to mitogens (ConA, LPS) and NK cell cytotoxic activity assays.
• Thymus and lymphoid organ histopathology to document anatomical defects.
• SPF microbiological screening: viral serology (e.g., MHV, MNV, MPV, Sendai, PVM, REO3, Ectromelia, rotavirus), bacterial culture and PCR (Helicobacter spp., Pasteurella, CAR bacillus), and parasitological examination.
• Human cell chimerism assessment: human CD45+ percentage and lineage reconstitution (CD3, CD19, CD33, CD56) in blood and lymphoid tissues.
• Xenograft performance metrics: tumor take rate, doubling time, growth kinetics, and passage stability for PDX models.
• Baseline health data: body weight curves, hematology, serum chemistry, and survival/longevity profiling.

Testing Methods

Genotyping and Sequencing

Allele-specific PCR followed by Sanger sequencing confirms the exact edit at the target locus. Quantitative PCR or digital droplet PCR is applied for copy number determination, while targeted deep sequencing of predicted off-target sites supports genomic safety evaluation of edited founders.

Flow Cytometric Immunophenotyping

Multiparameter flow cytometry with standardized gating strategies and fluorescence-minus-one controls is the reference method for enumerating lymphocyte subsets. For severe immunodeficient strains, the expected result is near-complete absence of T and B cells, and, for IL2Rγ-null strains, absence of NK cells. In humanized models, human CD45 versus mouse CD45 discrimination quantifies reconstitution efficiency.

Serological and Molecular Microbiology

Health monitoring programs combine ELISA-based viral serology, real-time PCR pathogen panels, bacteriological culture, and parasitological flotation methods in accordance with GB 14922.1 and GB 14922.2 requirements for SPF colonies. Environmental parameters such as temperature, humidity, ventilation, and pressure differentials are verified against GB 14925 facility criteria.

Functional Engraftment and Efficacy Evaluation

Model permissiveness is validated through standardized xenograft challenge studies using well-characterized human tumor cell lines or PDX tissues, with subcutaneous and orthotopic inoculation routes, bioluminescent imaging where applicable, and calculation of tumor growth inhibition (TGI) in treatment cohorts. HSC humanization is validated by serial blood sampling at defined intervals (typically weeks 8–16 post-infusion) to document stable human chimerism above predefined acceptance thresholds.

Quality and Data Integrity Practices

• Study design with prospective randomization, blinding, and statistical power calculation.
• Electronic data capture with audit trails consistent with data integrity principles.
• Method validation covering specificity, sensitivity, repeatability, and robustness.
• Animal welfare compliance with the 3Rs principles and applicable national laboratory animal regulations, consistent with the animal welfare provisions of ISO 10993-2 for biological evaluation studies.

Applications

• Oncology research: cell-line-derived xenografts (CDX), patient-derived xenografts (PDX), orthotopic and metastatic models for efficacy and pharmacodynamic studies.
• Immuno-oncology: evaluation of checkpoint inhibitors (anti-PD-1/PD-L1, anti-CTLA-4), bispecific antibodies, and CAR-T or NK cell therapies in humanized hosts.
• Hematopoiesis and immunology: studies of human HSC homing, differentiation, and lineage development.
• Stem cell and regenerative medicine: teratoma formation assays, tissue-engineered construct evaluation, and cell therapy safety testing.
• Infectious disease modeling: replication-competent studies of HIV, emerging viruses, and other human pathogens requiring human-targeted models.
• Transplantation and graft-versus-host disease: allogeneic and xenogeneic graft acceptance studies.
• Preclinical drug development: in vivo efficacy, safety, and toxicology support under GLP-aligned study conditions.
• Biomedical material assessment: in vivo performance screening of biomaterials and medical device candidates in immunologically permissive hosts.

FAQ

What is the difference between NOD-SCID and NSG-class mice?

NOD-SCID mice lack T and B cells and carry additional innate immune defects from the NOD background, but retain functional NK cells that limit human cell engraftment. NSG-class strains add a knockout of the IL2 receptor gamma chain, eliminating NK cells and disabling multiple cytokine signaling pathways, which substantially improves human HSC engraftment and PDX success rates.

How is the degree of immune humanization quantified?

Humanization is quantified by flow cytometric measurement of human CD45+ cells as a percentage of total CD45+ (human plus mouse) leukocytes in peripheral blood, typically supported by endpoint analysis of bone marrow and spleen. Lineage markers (CD3, CD19, CD33, CD56) confirm multi-lineage human reconstitution, and functional assays verify responsiveness of the reconstituted immune compartment.

What is SCID "leakiness" and how is it monitored?

Leakiness refers to the partial appearance of oligoclonal T and B lymphocytes in a subset of aging SCID mice, which can compromise experimental consistency. Colonies are monitored by periodic flow cytometry for lymphocyte reappearance and by serum immunoglobulin ELISA, and leaky animals are excluded from breeding and studies.

Which microbiological and facility standards apply?

SPF colonies are monitored against the microbiological and parasitological criteria specified in GB 14922.1 and GB 14922.2, with genetic quality controlled per GB 14923 and housing facilities validated against GB 14925. Facility quality management is commonly reinforced through ISO 9001-aligned processes.

How long does model construction and full validation take?

Gene-edited founders are typically obtained within three to four months, followed by several months of breeding to homozygosity and background stabilization. Complete validation—covering genotyping, immunophenotyping, microbiological clearance, and functional engraftment testing—generally requires six to twelve months overall, while PDX establishment adds an additional three to six months depending on tumor type.

How are immunodeficient animals housed to maintain quality?

Animals are maintained in barrier facilities using individually ventilated cages, sterilized bedding, irradiated or autoclaved feed, and sterile drinking water, with strict personnel and material flow controls. This management, combined with scheduled health monitoring by accredited third-party laboratories, preserves SPF status and experimental reproducibility.